Načítá se...

73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)

BACKGROUND: Palivizumabis a monoclonal antibody for preventionof serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in high risk children. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), prematurity (≤ 35 weeks gestational age...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Paediatr Child Health
Hlavní autoři: Mitchell, Ian, Saleem, Mahwesh, Li, Abby, Lanctot, Krista, Paes, Bosco
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6543311/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/pch/pxz066.072
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!